Protara Therapeutics
TARA
34 hedge funds and large institutions have $18.3M invested in Protara Therapeutics in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
125% more capital invested
Capital invested by funds: $8.17M → $18.3M (+$10.2M)
14% more call options, than puts
Call options by funds: $92K | Put options by funds: $81K
13% more funds holding
Funds holding: 30 → 34 (+4)
1.66% more ownership
Funds ownership: 38.33% → 39.99% (+1.7%)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
+$544K |
| 2 |
Truist Financial
Charlotte,
North Carolina
|
+$64.5K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$57.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$56.1K |
| 5 |
LPL Financial
San Diego,
California
|
+$51.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$92.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$39K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$29.7K |
| 4 |
Millennium Management
New York
|
-$21.5K |
| 5 |
Two Sigma Investments
New York
|
-$17.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Acadian Asset Management
Boston,
Massachusetts
| $25K | – | – | – |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $16K | +$10.5K | +3,258 | +448% |
|
28
UBS Group
Zurich,
Switzerland
| $14.9K | +$9.06K | +2,809 | +307% |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $10.3K | -$5.67K | -1,758 | -41% |
|
|
ACM
30
ADAR1 Capital Management
Austin,
Texas
| $8.02K | -$626 | -194 | -9% |
|
31
Wells Fargo
San Francisco,
California
| $2.29K | +$3 | +1 | +0.2% |
|
32
Osaic Holdings
Scottsdale,
Arizona
| $401 | – | – | – |
|
33
JP Morgan Chase
New York
| $88 | +$19 | +6 | +38% |
|
34
Qube Research & Technologies (QRT)
London,
United Kingdom
| $8 | – | – | – |
|
|
35
Assenagon Asset Management
Senningerberg,
Luxembourg
| – | -$29.7K | -15,831 | Closed |
|
|
36
Millennium Management
New York
| – | -$21.5K | -11,506 | Closed |
|
37
Bank of America
Charlotte,
North Carolina
| – | -$11 | -6 | Closed |
|
TARA Hedge Fund Activity: Q1 2024 in Review
34 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2024, worth a combined $18.3M — up 125% from $8.17M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TARA positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Stempoint Capital, opening a new position worth an estimated $544K. The largest seller was Renaissance Technologies, cutting an estimated $92.6K.
- 34 institutional investors held Protara Therapeutics (TARA) as of Q1 2024, up from 30 in Q4 2023.
- Funds reported $18.3M of Protara Therapeutics stock for Q1 2024, up 125% quarter-over-quarter.
- 7 funds opened new Protara Therapeutics positions in Q1 2024 and 3 closed out, a net change of +4 holders.
- The largest Protara Therapeutics buyer in Q1 2024 was Stempoint Capital, an estimated $544K added.
- The largest Protara Therapeutics seller in Q1 2024 was Renaissance Technologies, an estimated $92.6K sold.
Based on aggregated 13F filings for Q1 2024.